Ongoing salami salmonella outbreak expands
The expansion of a salami recall due to salmonella leads MedicalWatch for July 15, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
21 minutes ago
- CTV News
‘Not going down without a fight': Warranty battle with local homebuilder
Homeowners Michael and Susanne Beaudoin in front of their home in Belle River, Ont., on July 17, 2025. (Stefanie Masotti/CTV News Windsor) A Belle River couple say they are emotionally and financially depleted trying to fix hundreds of thousands of dollars in deficiencies to their 2500 sq. foot new construction home. 'We've tried so hard to make sure that we've provided our children with a lovely life, and now we're stuck,' said homeowner Suzanne Beaudoin and her husband Michael about what supposed to be their 'dream home.' Before they moved into the house in 2016, they had what's called a pre-possession inspection with the homebuilder, Everjonge Homes. They say they address obvious concerns to the homebuilder. 'He fluffed it off,' said Suzanne Beaudoin who told CTV News Everjonge Homes told them the deficiencies where quote 'satisfactory.' But the deficiencies escalated overtime. 'There was a big storm. We ended up taking the walls out,' she said. 'We had black mold everywhere.' Home concerns The dining room wall of the Beaudoin's home in Belle River, Ont. (Source: Michael and Susanne Beaudoin) Suzanne says it turned out to be a massive leak coming from the side wall from one bedroom, through the garage, into the dining room and into the basement. They say they contacted their insurance company, who told them the water damage could not be filed as a claim and that it's the responsibility if of the homebuilder. A month later, they say, that insurance company canceled their policy. Home baseboard The Beaudoins say there was black mold in their home in Belle River, Ont. (Source: Michael and Suzanne Beaudoin) In 2019, the couple launched a lawsuit against Everjonge Homes. They say it hasn't helped. 'It's been five years of this lawsuit, and we are stuck,' Suzanne Beaudoin said as they no longer can afford lawyers. The Beaudoin's acquired an independent engineering report, they say, cost them roughly $10,000 identifying all visible deficiencies including the lack of proper waterproofing around doors, windows and the envelopment of the home creating unwanted moisture and mold. 'I've been very sick from it. I'm have chronic headaches, migraines,' said Suzanne Beaudoin. 'The breathing issues, the asthma. The kids have it. My son, who has asthma, he's the worst.' They tell CTV News an independent homebuilder from Sarnia analyzed the home and estimates damage to be upwards of $1 million, due to inadequate waterproofing of doors, windows and the envelopment of the home creating unwanted moisture and mold. It's a dollar figure the Beaudoin's can't afford. 'We paid them for a product that they did not properly deliver,' Suzanne Beaudoin. In an email sent to CTV News, EverJonge Homes Ltd writes 'As this matter is currently the subject of ongoing litigation, we are unable to provide comment at this time.' 'I'm not leaving this home. We fought hard to have it. We fought hard to keep it,' said Suzanne Beaudoin. 'I'm not leaving and I'm not going to back down without a fight.'
Globe and Mail
21 minutes ago
- Globe and Mail
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
Johnson & Johnson JNJ reported stronger-than-expected second-quarter 2025 results. The world's biggest healthcare products maker continued with its long streak of earnings beat and also exceeded revenue estimates. It also lifted its revenue guidance for this year and boosted its quarterly dividends. Shares of JNJ rallied 6.1% following the earnings announcement. Investors should tap the company's growth prospects through ETFs with the largest allocation to this diversified drug maker. These include iShares U.S. Pharmaceuticals ETF IHE, VanEck Vectors Pharmaceutical ETF PPH, Health Care Select Sector SPDR Fund XLV, iShares U.S. Healthcare ETF IYH and First Trust Nasdaq Pharmaceuticals ETF FTXH. JNJ's earnings per share came in at $2.77, which beat the Zacks Consensus Estimate of $2.66 but declined 1.8% from the year-ago earnings. Revenues grew 5.8% year over year to $23.74 billion and outpaced the Zacks Consensus Estimate of $22.80 billion (see: all the Healthcare ETFs here). Innovative Medicines sales advanced 4.9%, while sales from MedTech devices jumped 7.3%. Sales of JNJ's top-selling blood cancer treatment, Darzalex, jumped 23% to $3.5 billion, while Xarelto generated $621 million in sales, up 5.6% year over year. However, sales of psoriasis drug Stelara declined 42.7% to $1.65 billion due to the launch of several biosimilar versions. Invega Sustenna sales also dropped 5.9% to $992 million. Johnson & Johnson raised its revenue guidance for fiscal 2025 to $93.2-$93.6 billion from $91.0-$91.8 billion, indicating year-over-year growth of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The company also lifted its adjusted earnings per share guidance to $10.80-$10.90 from $10.50-$10.70 due to a stronger top-line performance and a reduced expected impact from tariffs. The drugmaker now anticipates a $200 million tariff impact in 2025, down from its previous estimate of $400 million. Following the upbeat results, Stifel has raised its price target on Johnson & Johnson to $165.00 from $155.00, citing that multiple new product launches have driven the company's confidence. The company also lifted its quarterly dividend to $1.30 per share from $1.24, marking its 63rd consecutive annual increase. At this new rate, the annual dividend totals $5.20 per share, up from $4.96. ETFs in Focus iShares U.S. Pharmaceuticals ETF (IHE) iShares U.S. Pharmaceuticals ETF provides exposure to 36 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Johnson and Johnson takes the top spot, accounting for a 22.7% share. iShares U.S. Pharmaceuticals ETF has $561.2 million in AUM and charges 39 bps in fees and expenses. Volume is good at about 54,000 shares a day. The fund has a Zacks ETF Rank #3 (Hold) with a High risk outlook (read: Pharma ETFs in Focus on Trump's Drug Price Overhaul). VanEck Vectors Pharmaceutical ETF (PPH) VanEck Vectors Pharmaceutical ETF follows the MVIS US Listed Pharmaceutical 25 Index, which measures the performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well as production, marketing and sales of pharmaceuticals. It holds 25 stocks in its basket, with Johnson and Johnson occupying the second position at 10.3% of the assets. VanEck Vectors Pharmaceutical ETF has amassed $534.6 million in its asset base and trades in a good volume of about 437,000 shares a day. The expense ratio is 0.36%. VanEck Vectors Pharmaceutical ETF has a Zacks ETF Rank #3 with a Medium risk outlook. Health Care Select Sector SPDR Fund (XLV) Health Care Select Sector SPDR Fund is the most popular healthcare ETF and follows the Health Care Select Sector Index. It holds 60 securities in its basket, with JNJ taking the second spot at 7.7% of the assets. Pharma, healthcare equipment & supplies, and healthcare providers and services have a significant share at 31.2%, 24.7% and 17.9%, respectively. Health Care Select Sector SPDR Fund manages $33.8 billion in its asset base and trades in a heavy volume of around 14 million shares. The expense ratio comes in at 0.08%. It has a Zacks ETF Rank #1 (Strong Buy) with a Medium risk outlook (read: House Passes Trump's "Big, Beautiful Bill": ETFs in Focus). iShares U.S. Healthcare ETF (IYH) iShares U.S. Healthcare ETF offers exposure to 103 U.S. healthcare equipment and services, pharmaceuticals, and biotechnology companies by tracking the Russell 1000 Health Care RIC 22.5/45 Capped Gross Index. Johnson and Johnson is the top firm, accounting for 7.5% of the total assets. In terms of industrial exposure, pharma takes the top spot at 31.1%, followed by healthcare equipment (23.6%) and biotech (20.3%). iShares U.S. Healthcare ETF has amassed $2.7 billion in its asset base while charging 39 bps in annual fees. It trades in a good volume of around 528,000 shares a day and has a Zacks ETF Rank #3 with a Medium risk outlook. First Trust Nasdaq Pharmaceuticals ETF (FTXH) First Trust Nasdaq Pharmaceuticals ETF offers exposure to U.S. companies within the pharmaceuticals industry and tracks the Nasdaq US Smart Pharmaceuticals Index. It holds 49 securities in its basket, with JNJ occupying the top spot at 7.5% of the assets. FTXH has a lower AUM of $14.6 million and an average daily volume of 14,000 shares. First Trust Nasdaq Pharmaceuticals ETF charges 60 bps in annual fees and has a Zacks ETF Rank #3. Want key ETF info delivered straight to your inbox? Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report iShares U.S. Healthcare ETF (IYH): ETF Research Reports iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceutical ETF (PPH): ETF Research Reports First Trust NASDAQ Pharmaceuticals ETF (FTXH): ETF Research Reports This article originally published on Zacks Investment Research (
CTV News
an hour ago
- CTV News
How Manitobans can stay safe from wildfire smoke
Clouds of smoke rise from the Cross Lake community in northern Manitoba. (Raymond Robinson) With many communities under air quality warnings, it's important for Manitobans to stay safe and protect their lungs from wildfire smoke. According to the latest provincial data, there are 123 active wildfires across the province and 310 wildfires so far this year. This year's wildfire season is also on track to be Canada's second worst on record. 'The 2025 season is very aggressive,' said Juliette Mucha from the Manitoba Lung Association in an interview with CTV Morning Live on Thursday. 'But what we're caught off guard with is it started so early this year, so it's lasting a long time.' Mucha said her organization wants to educate Manitobans on how they can best enjoy their summer while also staying protected against the smoke, which has the ability to travel hundreds of kilometres. She emphasized smoke can affect everyone, not just those with health conditions, such as asthma, COPD and pulmonary fibrosis. 'We have one set of lungs, and we need to take care of them,' she said. To stay safe amid a high air quality health index, Mucha recommends that people stay indoors as much as possible, drink plenty of water, and wear an N95 mask when going outside. She also recommends closing windows and doors at home, putting your air conditioner on recirculation mode, and using an air purifier with a HEPA filter. 'I encourage everyone, we have a lot of Manitoba events happening; enjoy, but take precautions,' she said.
